NAS:ONTX (USA) Also trade in: Germany

Onconova Therapeutics Inc

$ 3.35 -0.16 (-4.56%)
Volume: 41,610 Avg Vol (1m): 75,163
Market Cap $: 20.16 Mil Enterprise Value $: 9.76 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -378.86
Net Current Asset Value -0.29
Tangible Book -0.26
Projected FCF -55.77
Median P/S Value 2.43
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
77.74% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ONTX: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Equity-to-Asset -0.14
Equity-to-Asset ranked lower than
96.99% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ONTX: -0.14
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -2.99, Med: 0.3, Max: 0.77
Current: -0.14
-2.99
0.77
Interest Coverage No Debt
Interest Coverage ranked higher than
73.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
ONTX: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -53.40
DISTRESS
GREY
SAFE
Beneish M-Score -0.69
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 24.96%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -3363.52
Operating Margin ranked lower than
83.21% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ONTX: -3363.52
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -7968, Med: -1581.69, Max: -48.23
Current: -3363.52
-7968
-48.23
Net Margin % -3153.42
Net Margin ranked lower than
81.69% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ONTX: -3153.42
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -7960.25, Med: -1495.6, Max: -64.76
Current: -3153.42
-7960.25
-64.76
ROE % -503.53
ROE ranked lower than
100.00% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ONTX: -503.53
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -503.53, Med: -146.4, Max: -123.46
Current: -503.53
-503.53
-123.46
ROA % -126.53
ROA ranked lower than
93.91% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ONTX: -126.53
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -589.29, Med: -83.9, Max: -66.18
Current: -126.53
-589.29
-66.18
ROC (Joel Greenblatt) % -109915.18
ROC (Joel Greenblatt) ranked lower than
91.60% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ONTX: -109915.18
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -109915.18, Med: -11629.79, Max: -4392.58
Current: -109915.18
-109915.18
-4392.58
3-Year Total Revenue Growth Rate -52.50
3-Year Revenue Growth Rate ranked lower than
78.80% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ONTX: -84.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -84.2, Med: -38.2, Max: -27.3
Current: -84.2
-84.2
-27.3
3-Year Total EBITDA Growth Rate 0.80
3-Year EBITDA Growth Rate ranked higher than
94.01% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ONTX: 67
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -20.4, Med: 54, Max: 67
Current: 67
-20.4
67
3-Year EPS w/o NRI Growth Rate 68.40
3-Year EPS w/o NRI Growth Rate ranked higher than
92.66% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ONTX: 68.4
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 55, Max: 68.4
Current: 68.4
0
68.4

» ONTX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ONTX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare OTCPK:RGRX XKRX:281310 AMEX:RNN OTCPK:ETST ASX:AHZ NAS:LIFE AMEX:NAVB NAS:NVLN BOM:540679 ASX:IVQ XSAT:SPAG OSL:BIOTEC NAS:TTNP OSTO:XINT OTCPK:IPIX AMEX:OGEN ASX:ACR NAS:CTXR LSE:HVO NAS:ADIL
Traded in other countries 0T22.Germany
Address 375 Pheasant Run, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. The key product candidate is Rigosertib which is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ratios

Current vs industry vs history
PS Ratio 20.76
PS Ratio ranked higher than
72.31% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ONTX: 20.76
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.45, Med: 15, Max: 130.19
Current: 20.76
0.45
130.19
EV-to-EBIT -0.40
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ONTX: -0.4
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -5.8, Med: -0.3, Max: 0.8
Current: -0.4
-5.8
0.8
EV-to-EBITDA -0.43
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ONTX: -0.43
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -5.8, Med: -0.3, Max: 0.8
Current: -0.43
-5.8
0.8
EV-to-Revenue 13.35
EV-to-Revenue ranked lower than
60.05% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ONTX: 13.35
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -5.1, Med: 8.25, Max: 75.9
Current: 13.35
-5.1
75.9
Current Ratio 1.33
Current Ratio ranked lower than
90.60% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ONTX: 1.33
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.32, Med: 2.82, Max: 10.1
Current: 1.33
0.32
10.1
Quick Ratio 1.33
Quick Ratio ranked lower than
88.08% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ONTX: 1.33
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.32, Med: 2.82, Max: 10.1
Current: 1.33
0.32
10.1

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -189.50
3-Year Share Buyback Rate ranked lower than
90.32% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ONTX: -189.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -189.5, Med: -47.6, Max: -10.8
Current: -189.5
-189.5
-10.8

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 1.38
Price-to-Median-PS-Value ranked higher than
85.10% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ONTX: 1.38
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0, Med: 1.4, Max: 13.05
Current: 1.38
0
13.05
Earnings Yield (Joel Greenblatt) % -254.50
Earnings Yield (Greenblatt) ranked lower than
91.95% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ONTX: -254.5
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -82162.5, Med: -169.4, Max: 19421.5
Current: -254.5
-82162.5
19421.5

More Statistics

Revenue (TTM) (Mil) $ 0.73
EPS (TTM) $ -4.13
Beta 3.76
Volatility % 87.82
52-Week Range $ 1.69 - 11.17
Shares Outstanding (Mil) 6

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y